Checkpoint Therapeutics Reaches BLA Alignment With FDA for Cosibelimab
By Chris Wack
Checkpoint Therapeutics said it has reached alignment with the Food and Drug Administration on its biologics license application resubmission strategy for its cosibelimab cancer treatment.
The oncology company said Monday it plans to move forward with a mid-year BLA resubmission seeking the U.S. marketing approval for cosibelimab. This is a potential new treatment for patients with metastatic or locally advanced cutaneous squamous cell carcinoma who aren't candidates for curative surgery or curative radiation.
In December 2023, the FDA issued a complete response letter for the cosibelimab BLA, which only cited findings that arose during a multi-sponsor inspection of Checkpoint's third-party contract manufacturing organization as approvability issues to address in a BLA resubmission.
The letter didn't state any concerns about the clinical data package, safety, or labeling for the approvability of cosibelimab.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
June 24, 2024 08:01 ET (12:01 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s Happening in the Markets This Week
-
Worst-Performing Stock ETFs of the Quarter
-
Q3 in Review and Q4 2024 Market Outlook
-
Top-Performing Stock ETFs of the Quarter
-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Consumer Defensives: Despite Angst, Thirsty Investors Have Names to Pursue
-
Industrials: Many Stocks Overvalued After Q3 Outperformance
-
Basic Materials: Despite Index Rise, We See Multiple Long-Term Opportunities
-
What the Election Could Mean for Big Tech Stocks
-
3 Lessons From Recent Stock Market Drama
-
Consumer Cyclicals: Even Amid Moderating Consumer Spending, We See Discounts
-
Healthcare: Valuations Look Fair Overall, With Select Industries Still Undervalued
-
Utilities: Falling Interest Rates, Growth Outlook Boosting Stocks